This article has Open Peer Review reports available.
Targeting of human interleukin-12B by small hairpin RNAs in xenografted psoriatic skin
© Bak et al; licensee BioMed Central Ltd. 2011
Received: 14 April 2010
Accepted: 27 February 2011
Published: 27 February 2011
Psoriasis is a chronic inflammatory skin disorder that shows as erythematous and scaly lesions. The pathogenesis of psoriasis is driven by a dysregulation of the immune system which leads to an altered cytokine production. Proinflammatory cytokines that are up-regulated in psoriasis include tumor necrosis factor alpha (TNFα), interleukin-12 (IL-12), and IL-23 for which monoclonal antibodies have already been approved for clinical use. We have previously documented the therapeutic applicability of targeting TNFα mRNA for RNA interference-mediated down-regulation by anti-TNFα small hairpin RNAs (shRNAs) delivered by lentiviral vectors to xenografted psoriatic skin. The present report aims at targeting mRNA encoding the shared p40 subunit (IL-12B) of IL-12 and IL-23 by cellular transduction with lentiviral vectors encoding anti-IL12B shRNAs.
Effective anti-IL12B shRNAs are identified among a panel of shRNAs by potency measurements in cultured cells. The efficiency and persistency of lentiviral gene delivery to xenografted human skin are investigated by bioluminescence analysis of skin treated with lentiviral vectors encoding the luciferase gene. shRNA-expressing lentiviral vectors are intradermally injected in xenografted psoriatic skin and the effects of the treatment evaluated by clinical psoriasis scoring, by measurements of epidermal thickness, and IL-12B mRNA levels.
Potent and persistent transgene expression following a single intradermal injection of lentiviral vectors in xenografted human skin is reported. Stable IL-12B mRNA knockdown and reduced epidermal thickness are achieved three weeks after treatment of xenografted psoriatic skin with lentivirus-encoded anti-IL12B shRNAs. These findings mimick the results obtained with anti-TNFα shRNAs but, in contrast to anti-TNFα treatment, anti-IL12B shRNAs do not ameliorate the psoriatic phenotype as evaluated by semi-quantitative clinical scoring and by immunohistological examination.
Our studies consolidate the properties of lentiviral vectors as a tool for potent gene delivery and for evaluation of mRNA targets for anti-inflammatory therapy. However, in contrast to local anti-TNFα treatment, the therapeutic potential of targeting IL-12B at the RNA level in psoriasis is questioned.
Psoriasis is a chronic inflammatory skin disorder generally manifesting itself as symmetrical, erythematous, and scaling papules and plaques. The disease affects approximately 2-3% of the population worldwide and has a negative impact on the physical wellbeing and the quality of life [1–5]. Histologically, psoriasis displays epidermal hyperplasia, parakeratosis, thinning of stratum granulosum, and dilated and prominent vascularization of the dermis associated with an increased cellular infiltrate of immune cells. The exact cause of psoriasis is unknown, but it is widely accepted that a dysregulated immune system plays a pivotal role. Numerous pro-inflammatory cytokines are up-regulated in psoriasis and a normalization of the cytokine milieu has been shown to improve the disease phenotype [6–10]. For example, several inhibitors of tumor necrosis factor alpha (TNFα), which is considered one of the primary mediators of immune regulation, have been developed and proven successful in psoriasis treatment [11–13].
The pro-inflammatory cytokines interleukin-12 (IL-12) and IL-23 are both up-regulated in lesional psoriatic skin compared to non-lesional skin [14–17]. Both interleukins are expressed by activated denditric cells and macrophages present in the skin, but also to some extent by keratinocytes [17–19]. IL-12 stimulates the production of IFN-γ and the maturation of naïve T-cells into Th1 cells . IL-23 seems to play a crucial role in the survival and proliferation of Th17 cells, leading to the production of IL-17 and in turn the pro-inflammatory cytokines TNFα, IL-1, IL-6, IL-8, and IL-22. Genetic polymorphisms in IL-12B and one of the IL-23 receptor subunits (IL-23R), have been linked to psoriasis , and many of the current therapies used in treating psoriasis, such as narrow-band UVB therapy  and administration of Etanercept (soluble TNFα receptor)  or Alefacept (an antagonist of T cell activation)  all reduce levels of IL-23. IL-12 and IL-23 are considered important factors in initiating and driving the Th1 and Th17 cytokine profiles characteristic of psoriasis.
IL-12 and IL-23 share a common subunit, the p40 subunit (encoded by the IL-12B gene) with the implication that both interleukins can be inhibited simultaneously. This therapeutic approach was recently validated with the approval of the p40-targeting monoclonal antibody, Ustekinumab, for clinical use . In a phase III trial, Ustekinumab was shown to be more effective and requiring fewer injections than the TNFα-inhibitor Etanercept . Although biological therapeutics inhibiting cytokines have proven successful in the treatment of moderate to severe psoriasis, there is still an unmet need for treatments that are convenient, without side-effects or contra-indications, and well tolerated, especially for long-term treatment. Of note, the biological therapeutics used today are administered systemically, where topically and locally administered treatments may be more desirable in terms of reducing systemic side-effects.
We have previously documented the therapeutic applicability of targeting TNFα mRNA by lentiviral delivery of anti-TNFα RNA effectors to xenografted psoriatic skin . We tested here the hypothesis that targeting of IL-12B mRNA by RNA interference (RNAi)-mediated degradation is therapeutically relevant. RNAi is a natural cellular mechanism by which double-stranded RNAs (dsRNAs) are processed into ~21-nucleotide small interfering RNAs (siRNAs) which can mediate sequence-specific degradation of target RNAs . If synthetic siRNA duplexes or DNA encoding small hairpin RNAs (shRNAs) are transfected into cells they are efficiently processed by the RNAi machinery and enter the RNAi pathway [28, 29]. Thus, potent and specific down-regulation of a single gene can be achieved by siRNA/shRNA delivery, and this is already a widely established tool for gene suppression. shRNA delivery by human immunodeficiency virus-derived lentiviral vectors benefits from high transduction efficiency as well as specific and stable down-regulation of gene expression  due to the inherent property of lentiviruses to integrate the genetic cargo into the genome.
In the current report, we describe the establishment of a lentiviral vector platform for an easy one-step cloning of shRNA oligonucleotides. Employing this novel lentiviral vector, we screened a panel of shRNAs targeting different regions of IL-12B mRNA and identified a potent shRNA candidate which mediated efficient IL-12B mRNA knockdown in several in vitro assays. To investigate the therapeutic applicability of targeting IL-12B mRNA in psoriasis, we employed the psoriasis xenograft transplantation model . Administration of the clinically approved p40-targeting antibody, Ustekinumab, was included as a comparative control to validate the relevance of targeting IL-12B in this model. Efficient lentiviral transgene delivery to xenografted psoriatic skin was demonstrated by intradermal injection of lentiviral vectors encoding a luciferase reporter gene, and stable and persistent luciferase expression was monitored for more than three months. Lentiviral delivery of anti-IL-12B shRNAs resulted in reduction of epidermal thickness and reduction in IL-12B mRNA levels. However, clinical evaluation of the psoriatic phenotype and immunohistochemical examination of the skin grafts did not indicate clinical resolution in this model. Taken together, this suggests that RNAi-directed targeting of IL-12B mRNA in lesional psoriatic skin is not as clinically potent as targeting of TNFα-encoding mRNA .
Contruction of plasmids
Oligonucleotides used for creation of anti-IL12B shRNA expression cassettes
Oligonucleotide sequence (target sequences are underlined)
Sense: 5'-ctagccc cctcacctgtgacacccct actcgagaaggggtgtcacaggtgaggtttttggaaa-3'
Sense: 5'-ctagccc atgccagcattagcgtgcg actcgagacgcacgctaatgctggcattttttggaaa-3'
Sense: 5'-ctagccc ggtcttaggctctggcaaa actcgagatttgccagagcctaagacctttttggaaa-3'
Sense: 5'-ctagccc ggaatttggtccactgata actcgagatatcagtggaccaaattcctttttggaaa-3'
Sense: 5'-ctagccc gcagacagatgcaaagaaa actcgagatttctttgcatctgtctgctttttggaaa-3'
Sense: 5'-ctagccc gatgggaacgcaagagatact actcgagaagtatctcttgcgttcccatctttttggaaa-3'
Sense: 5'-ctagccc gggccttcatgctatttaa actcgagattaaatagcatgaaggccctttttggaaa-3'
To create the lentiviral vector encoding firefly luciferase (pLV/PGK-FLuc), the firefly luciferase gene was PCR-amplified from the commercially available pGL3-Control vector (Promega, Madison, WI, USA) using primers 5'-aaaggatccatggaagacgccaaaaaca-3' and 5'-aaactcgagttacacggcgatctttccgc-3'. The PCR product was cloned into the lentiviral vector, pCCL.WPS.PGK-Puro.WHV (described in ), using the BamHI/XhoI sites, replacing the puromycin resistance gene. To revert the 5-bp modification in the H1 promoter in the pCCL-PGK-Puro-H1-MCS-based shRNA-expressing vectors to the sequence of the original vector (pCCL-cPPT-PGK-puro-WPRE-LTR-H1-shTNFα, harboring the remains of a BglII site), an overlap extension PCR between two fragments flanking the 5-bp region was done. For both shRNA-encoding lentiviral vectors, the 5' fragment was amplified by primers 5'-ctgctgccggctctgcggcc-3' and 5'-ggggatctgtggtctcatacagaactta-3'. The 3' fragment was amplified using primers 5'-gttctgtatgagaccacagatccccgcagacagatgc-3' and 5'-ctctagcagcatctagagcg-3' (in case of pCCL-PGK-Puro-H1-shIL12B #5) and 5'-gttctgtatgagaccacagatccccgatgggaacgca-3' and 5'-ctctagcagcatctagagcg-3' (in case of pCCL-PGK-Puro-H1-shIL12B #6). Overlap extension PCRs between the 5' fragment and the 3' fragments were done by primers 5'-ctgctgccggctctgcggcc-3' and 5'-ctctagcagcatctagagcg-3'. The overlap extension PCR amplicons were inserted into the original lentiviral vectors using the XbaI and ApaI restriction sites. All constructs were verified by sequencing with BigDye® Terminator v.3.1 Cycle Sequencing Kit (Applied Biosystems, Foster City, CA, USA).
shRNA oligonucleotide design
The lentiviral construct encoding the irrelevant shRNA was constructed as described in . For shIL-12B #1-#7, the loop region in the shRNAs were chosen on the basis of that proposed by McIntyre and Fanning . The design of the shRNA oligonucleotides was to resemble the endogenous situation of the H1 promoter and the H1 RNA coding region (the RNA Component of Human RNase P). This includes a distance of 26-nt between the TATA-box and the transcriptional start site, three cytosines before the transcriptional start and five consecutive thymines functioning as a termination signal . The cleavage of the shRNA transcript at the termination site is after the second uridine yielding a 2-nt 3' overhang resembling that of endogenously processed pre-miRNAs . shIL12B #1 was adapted from an siRNA reported by Flynn et al. to target a sequence of the murine IL-12B with high homology to the human sequence . The target sequence was modified to match the human sequence. shIL12B #2 was adapted from an siRNA that has been reported by Borg et al. to efficiently target human IL-12B . shIL12B #3-#7 were predicted by online algorithms: shIL12B #3-#5 by Dharmacon's siDESIGN, shIL12B #6 by InvivoGen siRNA Wizard, and shIL12B #7 by Qiagen's BioPredSi. See table 1 for shRNA oligonucleotide sequences.
HeLa, HEK293, and 293T cells were cultured at standard conditions at 37˚C in 5% (v/v) CO2 and maintained in Dulbecco's modified Eagle's medium (Cambrex, Verviers, Belgium) supplemented with 10% fetal calf serum, penicillin (100 U/ml), streptomycin (0.1 mg/ml), and L-glutamine (265 mg/l).
Dual-Luciferase Reporter Assay
For co-transfection experiments, HEK293 cells were seeded in 24-well plates (1.9 × 104 cells/well) one day before transfection. Co-transfections were performed with a total of 0.4 μg DNA (0.36 μg shRNA-encoding lentiviral vector and 0.04 μg psiCHECK-IL12B vector) using FuGENE-6 (Roche, Basel, Switzerland) according to the manufacturer's protocol. Forty-eight hours post-transfection, Renilla and Firefly Luciferase activities were analyzed by the use of the Dual-Luciferase® Reporter Assay System (Promega, Madison, WI, USA) according to the manufacturer's protocol. Reactions were carried out in 96-well plates and luminescence readings were performed in a multisample platereading luminometer (Berthold, Bad Wild-bad, Germany). Renilla Luciferase activity was normalized to Firefly Luciferase activity and presented relative to the negative vehicle control (pCCL-PGK-Puro-H1-MCS).
In transduction studies of shRNA-encoding lentiviral vectors, HEK293 cells were seeded in 24-well plates (1.9 × 104 cells/well) and transduced at an MOI of 10. The viral supernatant was supplemented with 8 μg/ml polybrene (Sigma-Aldrich, Milwaukee, WI). One day post-transduction, transfections with 0.04 μg psiCHECK-IL12B vector using FuGENE-6 (Roche, Basel, Switzerland) were performed according to the manufacturer's protocol and luciferase activities were measured forty-eight hours post-transfection as described above. To make cell lines with stable expression of shRNAs from a single lentiviral insertion, HEK293 cells were seeded in 6-well plates (5 × 104 cells/well) one day before transduction. Lentiviral supernatants were serially diluted and supplemented with 8 μg/ml polybrene (Sigma-Aldrich, Milwaukee, WI). Transduced cells were grown in 1 μg/ml puromycin-containing medium (Sigma-Aldrich, Milwaukee, WI) after which cells from a well with a low colony-count were pooled and allowed to expand. Ten days post-transduction, these cells were seeded in 24-well plates (1.9 × 104 cells/well) and transfected the following day with 0.04 μg psiCHECK-IL12B vector using FuGENE-6 (Roche, Basel, Switzerland) according to the manufacturer's protocol and luciferase activities were measured forty-eight hours post-transfection as described above. All dual luciferase assay experiments were performed at least in triplicates.
Generation of the IL12B-expressing HeLa cell line, HeLa-IL12B
The Sleeping Beauty DNA transposon vector encoding IL-12B was created by amplification of IL-12B cDNA from the psiCHECK-IL12B vector with primers 5'-aaagcggccgcccattggactctccgtcctg-3' and 5'-aaagcggccgcgattacaaagaagagttttt-3'. eGFP was excised using NotI from a biscitronic DNA transposon vector, pT2/CMV-eGFP(s).SV40-neo. The IL-12B PCR amplicon was inserted into the vector in the sense orientation using the NotI sites. Transposition in the HeLa cell line was performed in 6-well plates into which 2 × 105 HeLa cells were seeded. Twenty-four hours later, the cells were co-transfected with 0.5 μg transposon vector and 0.5 μg of transposase-encoding vector (SB100X) using FuGene6 (Roche, Basel, Switzerland) according to manufacturer's protocol. The cells were selected for positive transposition by G418-supplemented medium (600 μg/mL) for ten days. From a well with a low colony-count, single clones were isolated to separate dishes and expanded. IL-12B mRNA expression analysis was performed by purification of RNA using the RNeasy Mini Kit (Qiagen, Valencia, California, USA) followed by first strand cDNA synthesis using AffinityScript™ QPCR cDNA Synthesis Kit (Stratagene, La Jolla, California, USA) according to manufacturer's protocol. IL-12B mRNA expression was confirmed by IL12B-specific PCR on first strand cDNA. A single HeLa-IL12B clone was chosen for subsequent experiments.
Lentiviral vectors were produced in 293T cells which were seeded in 10-cm dishes (4 × 106 cells/well). Twenty-four hours after, cells were calcium phosphate transfected with 3.75 μg pMD.2G, 3 μg pRSV-Rev, 13 μg pMDGP-Lg/RRE, and 13 μg lentiviral transfer vector. Forty-eight hours post-transfection, the viral supernatant was harvested and filtered in 0.45 μm filters to remove cellular debris (Sarstedt, Nümbrecht, Germany). The resulting lentiviral vectors were designated LV-shRNA (e.g. LV-shIL12B #6). Colony-forming titer assays were performed on HEK293 cells seeded in 6-well plates (5 × 104 cells/well) one day before transduction. Lentiviral supernatants were serially diluted and supplemented with 8 μg/ml polybrene (Sigma-Aldrich, Milwaukee, WI). Transduced cells were grown in 1 μg/ml puromycin-containing medium (Sigma-Aldrich, Milwaukee, WI) for seven days after which the number of colonies were counted in the wells. For in vivo transductions of xenografted human skin, the lentiviral vectors were ultra-centrifuged for 2 hours (4°C at 25000 r.p.m.) in a SW28 rotor (Beckman Coulter, Fullerton, CA, USA). Virus pellets were resuspended overnight in PBS (without CaCl2 and MgCl2) at 4°C in a volume of 1/300 of the original volume. The lentiviral vector yield was determined by measurements of p24 Gag protein using a HIV-1 p24 Antigen ELISA Kit (ZeptoMetrix, Buffalo, NY) according to manufacturer's protocol.
In vivo treatment of xenografted human skin by shIL12B-encoding lentiviral vectors and by p40-targeting antibodies
For evaluation of luciferase expression in human skin transduced with luciferase-encoding lentiviral vectors, skin grafts from a patient undergoing plastic surgery were obtained. For the evaluation of the effect of IL-12B knockdown in human psoriatic skin by shIL12B #6 or Ustekinumab (Stelera®, Janssen-Cilag, Birkerød, Denmark), psoriatic skin biopsies were obtained from seven patients with moderate to severe plaque psoriasis. The psoriasis of the participants was untreated for at least one month prior to biopsy acquisition. Informed patient consent was obtained and the study was approved by the Central Ethical Committee and conducted according to the Declaration of Helsinki protocols. Animal studies were carried out with permission from the Danish Experimental Animal Inspectorate. The xenotransplantation procedure was as follows: each skin biopsy, containing both epidermis and dermis, was split into several grafts (each 1.5 × 1.5 × 0.05 cm) and transplanted onto C.B-17 severe combined immunodeficient (SCID) mice, 6-8 weeks old (Taconic M & B, Silkeborg, Denmark), as described in . Shortly, the mice were anesthetized prior to surgery by a subcutaneous injection of Ketaminol (ketamine, 100 mg/kg; Intervet, Skovlunde, Denmark) and Narcoxyl (xylazine, 10 mg/kg; Intervet, Skovlunde, Denmark). The back was shaved and part of the exposed skin removed. The grafts were sutured with absorbable 6-0 suture (Caprosyn, Covidien, Dublin, Ireland) and covered with Xeroform dressings (Sherwood Medical Company; Markham, Ontario, Canada) for one week. The mice were kept under pathogen-free conditions throughout the study. The grafts healed for 10 days before treatment initiation. To evaluate luciferase expression in skin grafts and the effect of IL-12B knockdown by shRNA delivery, 150 μl LV-PGK-Fluc, LV-shIL12B #6 or LV-shIrrelevant were administered intradermally into the grafts as a single treatment (LV-PGK-Fluc was injected at a dose of 6.45 μg p24 Gag in 150 μL and the shRNA-encoding lentiviral vectors were injected at a dose of 30.1 ± 23.4 μg p24 Gag in 150 μL). As a positive control in the IL-12B knockdown study, Betnovat® (1 mg/g cream, GlaxoSmithKline Pharma) was applied once daily for the duration of the three-week treatment. As an additional negative control, a group of mice was left untreated. To evaluate the effect of p40 inhibition by treating the mice with the p40-targeting antibody, Ustekinumab, 200 μL Ustekinumab (0.9 mg/kg) or 200 μL negative control (0.9%sodium chloride solution) were administered to the mice intraperitoneally once weekly for the duration of the three-week treatment.
Evaluation of bioluminescence
Three mice receiving lentiviral vectors encoding firefly luciferase and one mouse left untreated were analyzed on day 3, 7, 11, 15, 18, 22, 37, 53, 80, and 98 for bioluminescence. Briefly, the mice were injected intraperitoneally with 200 μL luciferin (15 mg/mL) (Synchem OHG, Felsberg/Altenburg, Germany) and subsequently anesthetized with 3.75% isoflurane (Forene®, Abbott Scandinavia AB, Solna, Sweden). Anesthesia was maintained at 2% isoflurane while bioluminescence was analyzed using an IVIS® Spectrum (Caliper Life Sciences, Hopkinton, MA, USA) with the software Living Image® 4.0. Ten images were acquired at an interval of 2 minutes and peak-intensity images were selected for subsequent analysis. For quantification of bioluminescence from each skin graft, a region of interest was set with a lower threshold of 25% of maximum luminescence and average luminescence was measured within this region.
The semi-quantitative clinical psoriasis scores were assessed for each psoriatic xenograft twice weekly in a blinded fashion and scored according to the average of the following clinical signs: scaliness, induration and erythema. The parameters were scored using a four-point scale: 0, complete lack of cutaneous involvement; 1, slight involvement; 2, moderate involvement; 3, severe involvement. On this scale from 0 to 3, a maximal score of 3 represents severe scale, induration and erythema of the xenografted psoriatic skin. After treatment, biopsies from the centre of the graft were obtained and paraffin-embedded. Employing standard methods, sections were stained histochemically with haematoxylin and eosin. Epidermal thickness was measured at least ten random places from the stratum corneum to the deepest part of the rete pegs on three equally distant cut sections and the average value was calculated.
Skin biopsies from in vivo-transduced xenografted psoriatic skin were snap-frozen in liquid nitrogen and stored at -80°C. Biopsies were transferred to RNAlater-ICE (Ambion, Austin, TX, USA) and stored at -20°C for twenty-four hours prior to RNA isolation. From both in vitro cultured cells and skin biopsies, total RNA was extracted using the SV Total RNA Isolation System (Promega, Madison, WI, USA) according to manufacturer's protocol. The skin biopsies were homogenized in the lysis buffer for 2 × 2 minutes at 25 Hz using a TissueLyser (Qiagen, Valencia, California, USA). Isolated RNA was dissolved in nuclease-free water and stored at -80°C. First strand cDNA synthesis was performed using the iScript cDNA Synthesis Kit (Bio-Rad, Hercules, California, USA) according to manufacturer's protocol. Lentiviral transcripts were detected using a PCR amplifying part of the puromycin resistance gene and the woodchuck hepatitis element using primers 5'-caccgtcaccgccgacgtcg-3' (s) and 5'- gtcccggaaaggagctgac-3' (as). IL-12B mRNA levels were assessed by qRT-PCR employing the TaqMan® Gene Expression Master Mix (Applied Biosystems, Foster City, CA) according to manufacturer's protocol. IL-12B mRNA expression was determined using IL-12B primers and probes (FAM-labeled MGB-probes) (Hs01011518_m1, Applied Biosystems, Foster City, CA). IL-12B mRNA levels were normalized to the expression of the reference gene ribosomal protein, large, P0 (RPLP0) using RPLP0-specific primers (FAM-labeled MGB-probes) (Hs99999902_ml, Applied Biosystems, Foster City, CA). Expression of each gene was analyzed in at least duplicates using a LightCycler 480 (Roche, Basel, Switzerland). PCR conditions were 10 minutes at 95°C, 45 cycles of 15 seconds at 95°C and 60 seconds at 60°C. For all qPCR experiments, relative mRNA levels were determined using the relative standard curve method. Briefly, a standard curve for each gene was made from serial dilutions of the cDNA. The standard curve was then used to calculate relative amounts of target mRNA in the samples. Mean mRNA values were calculated and the data summarized as mean + SEM.
Tissue sections were immuno-stained with monoclonal rabbit anti-human antibodies against CD4 (clone SP 35, Cell Marque, Rocklin, CA, USA) and Ki-67 (Clone SP6, Spring Bioscience, Pleasanton, CA, USA), monoclonal mouse anti-human CD8 (M7103, Dako, Glostrup, Denmark), polyclonal goat anti-human antibodies against Elafin/SKALP (an epithelial proteinase inhibitor) (HP9025, Hycult Biotechnology, Uden, the Netherlands) and human β-defensin (hBD)-2 (an antimicrobial peptide) (500-P161G, Peprotech, London, UK). Elafin/SKALP and hBD-2 are both present in psoriasis skin but not in normal or atopic dermatitis skin . Prior to staining, antigens were retrieved in Tris-EGTA (TEG) buffer (pH = 9). Ki-67 was visualized by ultraview Universal HRP/DAB Detection Kit (Ventana Medical Systems, Tucson, AZ, USA), CD4 and CD8 were visualized by EnVision + System-HRP (DAB) kits for mouse and rabbit primary antibodies (Dako, Glostrup, Denmark). Signal was enhanced by 0.5% copper sulfate and nuclear staining was performed by Mayer's Haematoxylin. Elafin/SKALP was visualized by staining with rabbit anti-goat IgG secondary antibody (A21222, Alexa Fluor®, Molecular Probes, Eugene, OR) preceded by blocking of unspecific binding by normal rabbit serum (X0902, Dako, Glostrup, Denmark) and signal enhancing by Image-iT™ FX Signal Enhancer (Molecular Probes, Eugene, OR). hBD-2 was visualized by staining with Vectastain® ABC-AP Kit (AK-5005, Vector Laboratories, Burlingame, CA) and Vector® Red - Alkaline Phosphatase Substrate Kit I (SK-5100, Vector Laboratories, Burlingame, CA), following the manufacturer's instructions. Nuclear staining was performed by mounting samples in Prolong Gold anti-fade reagent (Molecular Probes, Eugene, OR).
The nonparametric Mann-Whitney test was used to test for differences between treatment groups in semi-quantitative clinical psoriasis scores. All other p-values were calculated by a two-tailed Student's t-test to test the null hypothesis of no difference between two compared groups. The assumption of equal variances was tested by the F-test. In all statistical analyses, p-values < 0.05 were considered significant.
Amelioration of the psoriatic phenotype in xenografted psoriatic skin following systemic injection of p40-targeting antibodies
The xenografted psoriatic skin was assessed throughout the study and a semiquantitative clinical psoriasis score based on erythema, thickness and scaliness of the psoriatic plaques was recorded twice weekly in a blinded fashion. After three weeks the mice were sacrificed and endpoint evaluation of the treatment of psoriasis was determined histologically by measuring epidermal thickness on three equally distantly cut hematoxylin and eosin-stained sections of the graft. All sections were blinded prior to measurements and evaluated randomly. As evident from Figure 1b, treatment with p40-targeting antibodies led to a significant improvement of the clinical phenotype of the psoriatic skin compared to the negative control. This was confirmed by measurements of the epidermal thickness of the skin grafts at treatment endpoint (Figure 1c). Average epidermal thickness of the skin grafts were reduced by 38% (438 mm to 273 mm) in the group treated with p40-targeting antibodies compared to the negative control group (p = 0.039). In conclusion, the high therapeutic potency of p40-targeting antibodies validates the relevance of studying p40-targeting in the xenograft transplantation model.
Potency screening of a panel of IL12B-targeting shRNAs
To identify potent shRNA variants targeting IL-12B mRNA, seven target sites in the IL-12B mRNA sequence were chosen, either predicted by online algorithms or adapted from previously published efficacious siRNAs. Four target sequences were located in the coding sequence and three were located in the 3' UTR (Figure 2b). To monitor shRNA knockdown potencies, each of the seven shRNA sequences were cloned into pCCL-PGK-Puro-H1-MCS and analyzed for the ability to target the IL-12B sequence by using a dual luciferase expression assay. By this approach, expression of the renilla luciferase reporter gene, when fused to the IL-12B sequence, was responsive to anti-IL12B shRNAs, whereas expression of the firefly luciferase from the same plasmid allowed normalization for transfection variations.
HEK293 cells were co-transfected with the psiCHECK-IL12B plasmid and the plasmid encoding the lentiviral vector used as an expression plasmid for episomal shRNA expression. Luciferase activities were measured forty-eight hours post-transfection and shRNA potencies were determined by normalizing to the level of expression obtained with the lentiviral plasmid not expressing any shRNA, utilized here as a negative control (vehicle). An shRNA not matching any known sequence in the human genome was used as an additional negative control (shIrrelevant) . As seen in Figure 2c shRNA potencies varied greatly, ranging from almost inactive to 87% down-regulation of the fusion transcript as seen for shIL12B #6.
Verification of full H1 promoter activity in the pCCL-PGK-Puro-H1-MCS vector
In the making of the lentiviral vector, pCCL-PGK-Puro-H1-MCS, for an easy one-step cloning of shRNA oligonucleotides, five base-pairs immediately upstream of the transcriptional initiation site in the H1 promoter were modified to accommodate the MCS, leaving the remains of an AvrII restriction site instead of that of a BglII restriction site (Figure 2d). It should be noted that the original lentiviral vector already harbored a 5-bp modification compared to the endogenous wild-type H1 promoter, indicating that this 5-bp region did not contain any cis-acting elements required for H1 promoter activity. However, to fully verify that shRNA expression and potency was not affected by this modification, the lentiviral constructs encoding the two most potent anti-IL12B shRNAs (#5 and #6) were reverted back to the original sequence (BglII) as reported by Raoul et al. by PCR site-directed mutagenesis. The two constructs with the remains of an AvrII and a BglII restriction site, respectively, were compared in the dual luciferase assay (Figure 2e). The two constructs encoding shIL12B #5 did not display any difference in shRNA potency. When expressed from the context of the new vector containing the shRNA insertion linker, shIL12B #6 elicited a marginally improved knockdown of the fusion transcript, indicating that the 5-bp mutation did not negatively affect shRNA expression and potency.
Stable IL-12B down-regulation following lentiviral transduction
To certify that the gene cassette encoding shIL12B #6 was efficiently transferred by the lentiviral vector system, we first measured the transductional efficiency of the shRNA-expressing vector in experiments that included the pCCL-PGK-Puro-H1-MCS vector as a control. High transduction titers of shRNA-expressing lentiviral vectors were confirmed (ranging from 1.6 × 106 to 5.3 × 106 colony-forming units per mL [cfu/mL] on HeLa cells), although the titers on average were reduced 4-fold relative to the control vector which did not express an shRNA (data not shown). Such findings are in agreement with previous studies that reported 5- to 6-fold decrease in viral titers presumably caused by shRNA expression and consequent targeting of the viral RNA genome during viral vector production .
To evaluate knockdown of an endogenously expressed target, which was not in the context of a fusion mRNA, an IL-12B expression cassette was inserted into the HeLa cell line by the means of the Sleeping Beauty DNA transposon system . IL-12B mRNA expression from the genomically inserted DNA transposon vector was confirmed by RT-PCR (data not shown), and the cell line was transduced with the shRNA-encoding lentiviral vectors at an MOI of 2. Endogenously expressed IL-12B mRNA was efficiently targeted by the lentivirally delivered shIL12B #6. The knockdown potency was evaluated by quantitative RT-PCR analysis of the transduced cells harvested two days post-transduction. We detected a 51% knockdown of IL-12B mRNA transcripts (Figure 3b) which demonstrated a high potential of lentiviral delivery of IL12B-directed shRNAs for efficient targeting of aberrantly expressed IL-12B for RNAi-mediated down-regulation.
Efficient and persistent cutaneous transgene expression following intradermal injection of lentiviral vectors in xenografted human skin
Targeting of IL-12B mRNA in xenografted psoriatic skin by lentiviral delivery of anti-IL12B shRNAs
As in the Ustekinumab study, the xenografted psoriatic skin was assessed throughout the study and assigned a semiquantitative clinical psoriasis score twice weekly in a blinded fashion. The mice were sacrificed after three weeks and treatment endpoint evaluation was determined by measuring epidermal thickness and by quantifying IL-12B mRNA levels in biopsies obtained from the psoriatic skin grafts. Since skin grafts treated with lentiviral vectors encoding shIrrelevant and the untreated skin grafts obtained similar semiquantitative clinical psoriasis scores for the duration of the experiment (p > 0.35 for all time points) and displayed similar epidermal thickness (p = 0.22) as well as similar degree of psorasiform papillae, Monroe's absess, vessel formation and parakeratosis, these two groups were pooled to one group, designated 'Negative control'.
As evident from Figure 5b, treatment with shIL12B-encoding lentiviral vectors did not seem to have an effect on the clinical phenotype of the psoriatic skin compared to the negative control. On day 3 and 7 we observed a difference in semiquantitative clinical psoriasis score of 0.5 and 0.4, respectively (p = 0.074 and p = 0.069) indicating a slight amelioration of the psoriatic phenotype. Treatment with the positive control, Betnovat, improved the psoriatic phenotype during the treatment course, however, the improvement at treatment endpoint was not significant (p = 0.12). Average epidermal thicknesses are shown in Figure 5c which shows that grafts injected with shIL12B-encoding lentiviral vectors exhibited a 27% reduction (414 mm to 304 mm) in average epidermal thickness compared to the negative control group. However, this reduction did not appear to be significant (p = 0.10). Betnovat, as expected, elicited a 42% reduction in epidermal thickness (p = 0.04). In addition to the epidermal thickness, IL-12B mRNA levels were quantified by qRT-PCR in the skin grafts. As evident from Figure 5d, treatment with shIL12B-encoding lentiviral vectors elicited a 45% reduction of IL-12B mRNA in the skin grafts in average. However, as in the case of epidermal thicknesses, this apparent reduction was not supported by statistical analysis (p = 0.19) probably ascribable to the limited number of skin grafts.
Finally, we carried out immunohistochemical stainings for characteristic molecular markers of psoriatic skin (Figure 5e). Neither stainings for Elafin/SKALP and hBD-2, which are both present in psoriatic but not in normal skin, nor for the cell proliferation marker Ki-67 revealed any effect of the treatment with shIL12B #6 relative to the shIrrelevant control. Furthermore, staining of skin-homing T-cells by use of antibodies targeting CD4 and CD8 did not show a difference between skin grafts treated with shIL12B #6 and shIrrelevant.
In conclusion, we saw only a marginal improvement of the psoriatic phenotype within the first week after efficient intradermal administration of lentiviral vectors encoding the highly potent IL12B-targeting shRNA. Measurements of epidermal thickness and IL-12B mRNA levels showed reductions of 27% and 45%, respectively, indicating that the vector-encoded shRNAs were actively targeting IL-12B mRNA in the skin. In summary, our data suggest that intradermally administered IL12B-targeting shRNAs impact the levels of IL-12B mRNAs and result in a reduced epidermal thickness that are very similar to the effects we have previously reported for shRNAs targeting TNFα mRNA . However, the psoriatic phenotype was not significantly affected by targeting IL-12B mRNA in the psoriasis xenograft transplantation model.
Our research group has previously provided evidence of the therapeutic efficacy of in vivo knockdown of TNFα mRNA in human skin facilitated by DNA-encoded shRNA molecules . This proof-of-concept study confirmed the therapeutic applicability of shRNA expression in skin and documented the potential use of RNAi in the treatment of psoriasis. In the present study, we extend the exploration of RNAi-mediated cytokine knockdown in human skin to include the common subunit of IL-12 and IL-23, p40, encoded by the IL-12B gene. The p40 subunit is a clinically validated therapeutic target in psoriasis, but it remains unclear if targeting IL-12B mRNA by RNAi-mediated degradation is therapeutically relevant.
The potency of any given shRNA is highly dependent on target sequence and context. Therefore, initial screening of a panel of shRNAs is necessary to identify a highly active variant. Indeed, in the initial luciferase-based screening of seven shRNAs targeting IL-12B, one shRNA candidate was identified, which was able to mediate a solid down-regulation of the renilla luciferase gene fused to full length IL-12B cDNA when expressed from either shRNA-encoding plasmids or lentiviral vectors. High shRNA potency was confirmed when the shRNA was expressed from a single lentiviral integration and after extrachromosomal non-integrated lentiviral vectors had been lost. Additionally, the highly varying potencies of the seven shRNA candidates confirmed the general need to improve the in silico algorithms for rational target prediction to minimize the initial screening work load in the identification of potent shRNA candidates. Furthermore, we found that the two already published siRNAs that efficiently target the murine  and human IL-12B  sequences, respectively, could not be successfully adapted to an shRNA context and maintain potency. We explain this by species sequence and target context variations and also by the fact that the efficiency of shRNA processing might also be sequence-dependent which could adversely affect the potency of an siRNA in an shRNA context.
Variations in target accessibility in the fusion mRNA context could influence RNAi activity and thus provide a false measurement of shRNA potency. This emphasizes the need to validate shRNA potency on native endogenously expressed targets. Moving the experimental setup to endogenously expressed targets showed that shRNA potencies were maintained even when shRNAs were expressed from few lentiviral insertions. High shRNA potency at low cellular concentrations is highly relevant for in vivo transduction of a tissue where there are a high number of target cells and cell accessibility is hampered compared to in vitro grown cells in monolayer.
The psoriasis xenograft transplantation model currently appears to be the best tool to screen anti-psoriatic therapeutic strategies in psoriasis before introducing them into to the clinic . Many already established anti-psoriatic therapies show similar results in the psoriasis xenotransplantation model as in the clinic. In line with these findings, we validated that the clinically approved p40-targeting antibody, Ustekinumab, led to a significant improvement of the psoriatic phenotype as evaluated by the semi-quantitative clinical psoriasis score and measurements of epidermal thickness in the psoriasis xenograft transplantation model.
Using the psoriasis xenograft transplantation model, we wished to evaluate if lentiviral delivery of shIL12B #6 could lower IL-12B mRNA levels and if this would have a beneficial effect on the disease phenotype. We found that IL-12B mRNA levels were reduced by 45% in the shIL12B-receiving skin grafts compared to the negative control. This result pointed towards the establishment of a stable knockdown of IL-12B which is consistent with our previous in vivo study of TNFα knockdown in human skin . Dendritic cells and macrophages in the upper dermal compartment (papillary dermis), and to some extent in the epidermis, have been shown to be the main source of IL-12 and IL-23, but epidermal keratinocytes also express both interleukins to a lesser extent . We have previously established that lentiviral vector-mediated eGFP transfer to xenografted psoriatic skin is more efficient in the epidermal compartment than the dermal compartment  and in our current setup, this could mean that interfering with IL-12B production in dermal dendritic cells and macrophages was limited by poor shRNA delivery. In contrast, the efficient transduction of epidermal keratinocytes implied that IL-12B knockdown in these cells was not limited by shRNA delivery.
Epidermal keratinocytes in psoriatic lesions have a transit time of 4-7 days from the basal layer to the stratum corneum meaning that the keratinocytes have been replenished several times during the three-week treatment . Hence, in order to stably knock down aberrant levels of IL-12B produced by epidermal keratinocytes throughout the treatment course, an efficient transduction of epidermal stem cells is required. Indeed, persistence of transgene expression from lentivirally transduced xenografted normal human skin was shown beyond the time span of keratinocyte transition from the basal membrane to the stratum corneum, implying that skin stem cells in the basal compartment were efficiently transduced (Figure 4).
Increased epidermal thickness is an important diagnostic hallmark of psoriasis and stable IL-12B knockdown seemed to result in a reduction in epidermal thickness by 27% (414 mm to 304 mm) in skin transduced with shIL12B-encoding lentiviral vectors compared to controls. This finding could be indicative of altered epidermal cell kinetics although no difference was seen in the immunohistochemical staining for the proliferative marker Ki-67. Nevertheless, a resulting clinical disease improvement was not apparent at treatment end-point even though a strong tendency towards this was seen at day 3 and 7 in the treatment course.
TNFα mRNA knockdown has a significant positive effect on the clinical psoriatic phenotype throughout the treatment course, whereas the effect of IL-12B mRNA knockdown in the current study is minimal. Such difference between targeting of IL-12B and of TNFα could hypothetically be explained by the different functions of the two cytokines. If IL-12 and IL-23 are less potent immune mediators than TNFα is, then TNFα knockdown may have a more profound therapeutic effect on psoriasis. The cytokines may also differ in abundance and redundancy, as well as the dynamics and kinetics of their immune signaling during inflammation. The cellular source of the aberrant expression of TNFα and IL-12B is somewhat similar . Therefore, although a difference in transduction efficiency of the various cellular constituents of the skin could influence the response to different cytokine-directed shRNAs, this may not necessarily explain our findings. Alternatively, the variation between cytokine targets may reflect differences in cytokine mRNA expression levels and, thus, the knockdown efficiencies that are required to obtain a therapeutic benefit. Although systemic treatment with anti-p40 monoclonal antibodies resulted in robust clinical improvement in the xenotransplantation model, we cannot exclude the possibility that a local RNA-directed treatment targeting IL-12B would require a longer time-frame (> 3 weeks to obtain a therapeutic effect and improve the disease phenotype.
The skin offers an attractive organ for RNAi-based therapeutics due to its ease of access. A therapeutic approach relying on lentiviral vector-mediated delivery of shRNAs to the skin is far from clinically relevant due to safety issues concerning the vector. So far, topical non-viral delivery of RNAi effectors have been hampered by poor penetrability of the stratum corneum, but recent advances have made it possible to deliver siRNAs formulated in a cream to the epidermis and dermis of murine skin at therapeutically relevant levels . Even though topical local delivery of siRNAs does not mediate a sustained RNAi effect, it has the potential to overcome multiple problems regarding systemic biological therapeutics including complications concerning patient-friendly administration, contra-indications, side-effects and patient adherence. Based on our current knowledge, we suggest that siRNAs targeting TNFα rather than IL-12B are further explored for clinical use.
Our studies show potent and sustained RNAi-mediated down-regulation of IL-12B mRNA by the use of lentiviral vectors. We document efficient lentiviral-mediated gene delivery and persistent gene expression in xenografted human skin. Down-regulation of IL-12B mRNA in xenografted psoriatic skin leads to a decrease in epidermal thickness, but not a clinical amelioration of the psoriatic phenotype in contrast to our previous studies targeting TNFα mRNA. Our studies question IL-12B mRNA as an optimal target for RNAi-directed treatment and, hence, further strengthen the need for validating therapeutic targets for such treatment. Small RNAs that mediate a cytokine-targeting RNAi response or interfere with endogenous cytokine regulation have the potential to become novel anti-inflammatory therapeutics, but additional obstacles such as off-targeting effects and poor delivery must be addressed before small RNAs can prove their therapeutic worth.
We thank Winnie Heidemann and Christian Knudsen for technical assistance. We also thank Daniel Miotto Dupont for help with biolumuniscence and the Danish Research Agency and the iNANO Centre at the University of Aarhus, Denmark, for providing equipment for bioluminescence imaging. Furthermore, this study was made possible through support by the Danish Medical Research Council, the Novo Nordisk Foundation, the Carlsberg Foundation, the Danish Cancer Society, Kgl. Hofbuntmager Aage Bangs Foundation, the Psoriasis Foundation, Helga and Peter Kornings Foundation, and the Augustinus Foundation. B.M. was funded by a grant from the Danish Cancer Society. R.O.B is funded by a grant from the Health Research Fund of Central Denmark Region and the Lundbeck foundation and R.O.B. is the recipient of a scholarship from the Novo Scholarship programme.
- Schon MP, Boehncke WH: Psoriasis. N Engl J Med 2005, 352: 1899–1912. 10.1056/NEJMra041320View ArticlePubMedGoogle Scholar
- Griffiths CE, Barker JN: Pathogenesis and clinical features of psoriasis. Lancet 2007, 370: 263–271. 10.1016/S0140-6736(07)61128-3View ArticlePubMedGoogle Scholar
- Kurd SK, Gelfand JM: The prevalence of previously diagnosed and undiagnosed psoriasis in US adults: results from NHANES 2003–2004. J Am Acad Dermatol 2009, 60: 218–224. 10.1016/j.jaad.2008.09.022View ArticlePubMedGoogle Scholar
- Hong J, Koo B, Koo J: The psychosocial and occupational impact of chronic skin disease. Dermatol Ther 2008, 21: 54–59. 10.1111/j.1529-8019.2008.00170.xView ArticlePubMedGoogle Scholar
- Zachariae R, Zachariae H, Blomqvist K, Davidsson S, Molin L, Mork C, Sigurgeirsson B: Quality of life in 6497 Nordic patients with psoriasis. Br J Dermatol 2002, 146: 1006–1016. 10.1046/j.1365-2133.2002.04742.xView ArticlePubMedGoogle Scholar
- Ghoreschi K, Thomas P, Breit S, Dugas M, Mailhammer R, van Eden W, van der Zee R, Biedermann T, Prinz J, Mack M, et al.: Interleukin-4 therapy of psoriasis induces Th2 responses and improves human autoimmune disease. Nat Med 2003, 9: 40–46. 10.1038/nm804View ArticlePubMedGoogle Scholar
- Stenderup K, Rosada C, Worsaae A, Dagnaes-Hansen F, Steiniche T, Hasselager E, Iversen LF, Zahn S, Woldike H, Holmberg HL, et al.: Interleukin-20 plays a critical role in maintenance and development of psoriasis in the human xenograft transplantation model. Br J Dermatol 2009, 160: 284–296. 10.1111/j.1365-2133.2008.08890.xView ArticlePubMedGoogle Scholar
- Jakobsen M, Stenderup K, Rosada C, Moldt B, Kamp S, Dam TN, Jensen TG, Mikkelsen JG: Amelioration of psoriasis by anti-TNF-alpha RNAi in the xenograft transplantation model. Mol Ther 2009, 17: 1743–1753. 10.1038/mt.2009.141View ArticlePubMedPubMed CentralGoogle Scholar
- Villadsen LS, Schuurman J, Beurskens F, Dam TN, Dagnaes-Hansen F, Skov L, Rygaard J, Voorhorst-Ogink MM, Gerritsen AF, van Dijk MA, et al.: Resolution of psoriasis upon blockade of IL-15 biological activity in a xenograft mouse model. J Clin Invest 2003, 112: 1571–1580.View ArticlePubMedPubMed CentralGoogle Scholar
- Caruso R, Botti E, Sarra M, Esposito M, Stolfi C, Diluvio L, Giustizieri ML, Pacciani V, Mazzotta A, Campione E, et al.: Involvement of interleukin-21 in the epidermal hyperplasia of psoriasis. Nat Med 2009, 15: 1013–1015. 10.1038/nm.1995View ArticlePubMedGoogle Scholar
- Schopf RE, Aust H, Knop J: Treatment of psoriasis with the chimeric monoclonal antibody against tumor necrosis factor alpha, infliximab. J Am Acad Dermatol 2002, 46: 886–891. 10.1067/mjd.2002.120472View ArticlePubMedGoogle Scholar
- Mease PJ, Goffe BS, Metz J, VanderStoep A, Finck B, Burge DJ: Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet 2000, 356: 385–390. 10.1016/S0140-6736(00)02530-7View ArticlePubMedGoogle Scholar
- Menter A, Tyring SK, Gordon K, Kimball AB, Leonardi CL, Langley RG, Strober BE, Kaul M, Gu Y, Okun M, Papp K: Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial. J Am Acad Dermatol 2008, 58: 106–115. 10.1016/j.jaad.2007.09.010View ArticlePubMedGoogle Scholar
- Arican O, Aral M, Sasmaz S, Ciragil P: Serum levels of TNF-alpha, IFN-gamma, IL-6, IL-8, IL-12, IL-17, and IL-18 in patients with active psoriasis and correlation with disease severity. Mediators Inflamm 2005, 2005: 273–279. 10.1155/MI.2005.273View ArticlePubMedPubMed CentralGoogle Scholar
- Lee E, Trepicchio WL, Oestreicher JL, Pittman D, Wang F, Chamian F, Dhodapkar M, Krueger JG: Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris. J Exp Med 2004, 199: 125–130. 10.1084/jem.20030451View ArticlePubMedPubMed CentralGoogle Scholar
- Yawalkar N, Tscharner GG, Hunger RE, Hassan AS: Increased expression of IL-12p70 and IL-23 by multiple dendritic cell and macrophage subsets in plaque psoriasis. J Dermatol Sci 2009, 54: 99–105. 10.1016/j.jdermsci.2009.01.003View ArticlePubMedGoogle Scholar
- Tonel G, Conrad C, Laggner U, Di Meglio P, Grys K, McClanahan TK, Blumenschein WM, Qin JZ, Xin H, Oldham E, et al.: Cutting Edge: A Critical Functional Role for IL-23 in Psoriasis. J Immunol 2010, 185: 5688–5691. 10.4049/jimmunol.1001538View ArticlePubMedPubMed CentralGoogle Scholar
- Gerosa F, Baldani-Guerra B, Lyakh LA, Batoni G, Esin S, Winkler-Pickett RT, Consolaro MR, De Marchi M, Giachino D, Robbiano A, et al.: Differential regulation of interleukin 12 and interleukin 23 production in human dendritic cells. J Exp Med 2008, 205: 1447–1461. 10.1084/jem.20071450View ArticlePubMedPubMed CentralGoogle Scholar
- Piskin G, Sylva-Steenland RM, Bos JD, Teunissen MB: In vitro and in situ expression of IL-23 by keratinocytes in healthy skin and psoriasis lesions: enhanced expression in psoriatic skin. J Immunol 2006, 176: 1908–1915.View ArticlePubMedGoogle Scholar
- Trinchieri G: Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol 2003, 3: 133–146. 10.1038/nri1001View ArticlePubMedGoogle Scholar
- Cargill M, Schrodi SJ, Chang M, Garcia VE, Brandon R, Callis KP, Matsunami N, Ardlie KG, Civello D, Catanese JJ, et al.: A large-scale genetic association study confirms IL12B and leads to the identification of IL23R as psoriasis-risk genes. Am J Hum Genet 2007, 80: 273–290. 10.1086/511051View ArticlePubMedGoogle Scholar
- Piskin G, Tursen U, Sylva-Steenland RM, Bos JD, Teunissen MB: Clinical improvement in chronic plaque-type psoriasis lesions after narrow-band UVB therapy is accompanied by a decrease in the expression of IFN-gamma inducers -- IL-12, IL-18 and IL-23. Exp Dermatol 2004, 13: 764–772. 10.1111/j.0906-6705.2004.00246.xView ArticlePubMedGoogle Scholar
- Gottlieb AB, Chamian F, Masud S, Cardinale I, Abello MV, Lowes MA, Chen F, Magliocco M, Krueger JG: TNF inhibition rapidly down-regulates multiple proinflammatory pathways in psoriasis plaques. J Immunol 2005, 175: 2721–2729.View ArticlePubMedGoogle Scholar
- Chamian F, Lowes MA, Lin SL, Lee E, Kikuchi T, Gilleaudeau P, Sullivan-Whalen M, Cardinale I, Khatcherian A, Novitskaya I, et al.: Alefacept reduces infiltrating T cells, activated dendritic cells, and inflammatory genes in psoriasis vulgaris. Proc Natl Acad Sci USA 2005, 102: 2075–2080. 10.1073/pnas.0409569102View ArticlePubMedPubMed CentralGoogle Scholar
- van de Kerkhof PC: Novel biologic therapies in development targeting IL-12/IL-23. J Eur Acad Dermatol Venereol 2010, 24(Suppl 6):5–9. 10.1111/j.1468-3083.2010.03830.xView ArticlePubMedGoogle Scholar
- Trial watch: novel biologic for psoriasis shows superiority over current best-seller Nat Rev Drug Discov 2008, 7: 880–881.Google Scholar
- Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC: Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 1998, 391: 806–811. 10.1038/35888View ArticlePubMedGoogle Scholar
- Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T: Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 2001, 411: 494–498. 10.1038/35078107View ArticlePubMedGoogle Scholar
- Brummelkamp TR, Bernards R, Agami R: A system for stable expression of short interfering RNAs in mammalian cells. Science 2002, 296: 550–553. 10.1126/science.1068999View ArticlePubMedGoogle Scholar
- Abbas-Terki T, Blanco-Bose W, Deglon N, Pralong W, Aebischer P: Lentiviral-mediated RNA interference. Hum Gene Ther 2002, 13: 2197–2201. 10.1089/104303402320987888View ArticlePubMedGoogle Scholar
- Dam TN, Kang S, Nickoloff BJ, Voorhees JJ: 1alpha,25-dihydroxycholecalciferol and cyclosporine suppress induction and promote resolution of psoriasis in human skin grafts transplanted on to SCID mice. J Invest Dermatol 1999, 113: 1082–1089. 10.1046/j.1523-1747.1999.00811.xView ArticlePubMedGoogle Scholar
- Raoul C, Abbas-Terki T, Bensadoun JC, Guillot S, Haase G, Szulc J, Henderson CE, Aebischer P: Lentiviral-mediated silencing of SOD1 through RNA interference retards disease onset and progression in a mouse model of ALS. Nat Med 2005, 11: 423–428. 10.1038/nm1207View ArticlePubMedGoogle Scholar
- Moldt B, Staunstrup NH, Jakobsen M, Yanez-Munoz RJ, Mikkelsen JG: Genomic insertion of lentiviral DNA circles directed by the yeast Flp recombinase. BMC Biotechnol 2008, 8: 60. 10.1186/1472-6750-8-60View ArticlePubMedPubMed CentralGoogle Scholar
- McIntyre GJ, Fanning GC: Design and cloning strategies for constructing shRNA expression vectors. BMC Biotechnol 2006, 6: 1. 10.1186/1472-6750-6-1View ArticlePubMedPubMed CentralGoogle Scholar
- Baer M, Nilsen TW, Costigan C, Altman S: Structure and transcription of a human gene for H1 RNA, the RNA component of human RNase P. Nucleic Acids Res 1990, 18: 97–103. 10.1093/nar/18.1.97View ArticlePubMedPubMed CentralGoogle Scholar
- Flynn MA, Casey DG, Todryk SM, Mahon BP: Efficient delivery of small interfering RNA for inhibition of IL-12p40 expression in vivo. J Inflamm (Lond) 2004, 1: 4. 10.1186/1476-9255-1-4View ArticleGoogle Scholar
- Borg C, Jalil A, Laderach D, Maruyama K, Wakasugi H, Charrier S, Ryffel B, Cambi A, Figdor C, Vainchenker W, et al.: NK cell activation by dendritic cells (DCs) requires the formation of a synapse leading to IL-12 polarization in DCs. Blood 2004, 104: 3267–3275. 10.1182/blood-2004-01-0380View ArticlePubMedGoogle Scholar
- de Jongh GJ, Zeeuwen PL, Kucharekova M, Pfundt R, van der Valk PG, Blokx W, Dogan A, Hiemstra PS, van de Kerkhof PC, Schalkwijk J: High expression levels of keratinocyte antimicrobial proteins in psoriasis compared with atopic dermatitis. J Invest Dermatol 2005, 125: 1163–1173. 10.1111/j.0022-202X.2005.23935.xView ArticlePubMedGoogle Scholar
- Thakker DR, Natt F, Husken D, Maier R, Muller M, van der Putten H, Hoyer D, Cryan JF: Neurochemical and behavioral consequences of widespread gene knockdown in the adult mouse brain by using nonviral RNA interference. Proc Natl Acad Sci USA 2004, 101: 17270–17275. 10.1073/pnas.0406214101View ArticlePubMedPubMed CentralGoogle Scholar
- Ivics Z, Hackett PB, Plasterk RH, Izsvak Z: Molecular reconstruction of Sleeping Beauty, a Tc1-like transposon from fish, and its transposition in human cells. Cell 1997, 91: 501–510. 10.1016/S0092-8674(00)80436-5View ArticlePubMedGoogle Scholar
- Boehncke WH: The psoriasis SCID mouse model: a tool for drug discovery? Ernst Schering Res Found Workshop 2005, 213–234. full_textGoogle Scholar
- Traub M, Marshall K: Psoriasis--pathophysiology, conventional, and alternative approaches to treatment. Altern Med Rev 2007, 12: 319–330.PubMedGoogle Scholar
- Nickoloff BJ, Karabin GD, Barker JN, Griffiths CE, Sarma V, Mitra RS, Elder JT, Kunkel SL, Dixit VM: Cellular localization of interleukin-8 and its inducer, tumor necrosis factor-alpha in psoriasis. Am J Pathol 1991, 138: 129–140.PubMedPubMed CentralGoogle Scholar
- Takanashi M, Oikawa K, Sudo K, Tanaka M, Fujita K, Ishikawa A, Nakae S, Kaspar RL, Matsuzaki M, Kudo M, Kuroda M: Therapeutic silencing of an endogenous gene by siRNA cream in an arthritis model mouse. Gene Ther 2009, 16: 982–989. 10.1038/gt.2009.66View ArticlePubMedGoogle Scholar
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-5945/11/5/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.